General American Investors Co. Inc. lowered its stake in shares of Repros Therapeutics Inc. (NASDAQ:RPRX) by 11.9% during the second quarter, Holdings Channel reports. The fund owned 519,829 shares of the biotechnology company’s stock after selling 69,939 shares during the period. General American Investors Co. Inc.’s holdings in Repros Therapeutics were worth $239,000 as of its most recent filing with the SEC.

Separately, Renaissance Technologies LLC boosted its stake in Repros Therapeutics by 7.4% in the fourth quarter. Renaissance Technologies LLC now owns 716,413 shares of the biotechnology company’s stock valued at $946,000 after buying an additional 49,300 shares during the last quarter. Institutional investors and hedge funds own 17.11% of the company’s stock.

Shares of Repros Therapeutics Inc. (NASDAQ RPRX) opened at 0.35 on Thursday. The company has a 50-day moving average of $0.41 and a 200 day moving average of $0.84. Repros Therapeutics Inc. has a 12 month low of $0.29 and a 12 month high of $2.48. The company’s market cap is $9.36 million.

Repros Therapeutics (NASDAQ:RPRX) last announced its earnings results on Tuesday, May 9th. The biotechnology company reported ($0.22) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.14) by $0.08. Repros Therapeutics had a negative net margin of 49,564.86% and a negative return on equity of 276.50%. The business had revenue of $0.01 million for the quarter. On average, analysts anticipate that Repros Therapeutics Inc. will post ($1.07) earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: This piece of content was originally reported by Watch List News and is the property of of Watch List News. If you are viewing this piece of content on another website, it was stolen and republished in violation of international trademark & copyright legislation. The legal version of this piece of content can be viewed at https://www.watchlistnews.com/repros-therapeutics-inc-nasdaqrprx-position-decreased-by-general-american-investors-co-inc/1467183.html.

Separately, Laidlaw cut shares of Repros Therapeutics from a “buy” rating to a “neutral” rating in a research report on Friday, July 21st.

About Repros Therapeutics

Repros Therapeutics, Inc is a biopharmaceutical company focused on the development of new drugs to treat hormonal and reproductive system disorders. The Company’s product candidates include enclomiphene, which is a single isomer of clomiphene citrate, an orally active small molecule compound, and Proellex, which is an orally administered selective blocker of the progesterone receptor in women, for the treatment of uterine fibroids and endometriosis.

Want to see what other hedge funds are holding RPRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Repros Therapeutics Inc. (NASDAQ:RPRX).

Institutional Ownership by Quarter for Repros Therapeutics (NASDAQ:RPRX)

Receive News & Ratings for Repros Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repros Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.